Science advances · 2026
Single-cell epigenetic profiling reveals a tumor-intrinsic interferon response program in ccRCC tied to poor prognosis and BAP1 loss.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Camp Sabrina Y, He Meng Xiao, Cuoco Michael S, Garza Amanda E, Xirenayi Sherin, Bakouny Ziad, Saad Eddy, El Masri Jad, Pimenta Erica, Meli Kevin, Labaki Chris, Titchen Breanna M, Kang Yun Jee, Horst Jack, Trowbridge Rachel, Shannon Erin, Helvie Karla, Thorner Aaron R, Vigneau Sébastien, Mayorga Angie, Kodali Jahnavi, Lachmayr Hannah, Bemus Meredith, Chen Pengsheng, Deng Haiteng, Park Jihye, Choueiri Toni K, Bi Kevin, Van Allen Eliezer M
Аннотация
Transcriptional programs in renal cell carcinoma (RCC) have been linked to tumor heterogeneity and clinical outcomes, but analogous efforts to define chromatin programs shaping disease biology have been limited. Here, we generated single-cell ATAC-seq profiles from patients with RCC and integrated them with three previously published datasets to identify chromatin programs in tumor cells. We identified an interferon response program enriched in BAP1-mutant tumors, and, in bulk ATAC-seq cohorts with linked clinical data, this program was associated with poor prognosis. Mechanistic analyses in isogenic models suggested that BAP1 loss induces a tumor-intrinsic interferon response, with dysregulated endogenous retroviruses as a potential upstream trigger. We further characterized the BAP1 mutation-associated tumor microenvironment across single-cell, bulk, and multiplex immunofluorescence data, identifying features of both inflammation and immune evasion. Together, our findings nominate tumor-intrinsic interferon signaling as a candidate driver of BAP1-associated aggressiveness in RCC and highlight immune evasion pathways as potential therapeutic targets.